Fig. 7

Effect of FERMT2, FKBP3, SMAD9, GATA2 and IHITH4 status on OS of LUAD patients. (a: Median survival time (MS) of LUAD patients with FERMT2 (−) and FERMT2 (+) was 41.4 months (95% CI, 37.1 to 45.2) and 21.70(95% CI,17.2 to 25.16), respectively, P = 0.0241. b: The MS of patients with FKBP3 (−) and FKBP3 (+) was 41.15 months (95% CI,36.23 to 46.72) and 20.25 (95% CI, 16.79 to 23.15), respectively, P = 0.0044. c: The MS of patients with SMAD9 (−) and SMAD9 (+) was 18.75 months (95% CI,13.15 to 23.38) and 34.05 (95% CI, 29.12 to 38.87), respectively, P = 0.0030. d: The MS of patients with GATA2 (−) and GATA2 (+) was 19.00 months (95% CI,14.47 to 24.13) and 37.10 (95% CI, 32.42 to 42.51), respectively, P = 0.0123. e: The MS of patients with ITIH4 (−) and ITIH4 (+) was 20.25 months (95% CI,15.14 to 25.42) and 34.05 (95% CI, 30.18 to 41.92), respectively, P = 0.0165)